Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK/Safety of Tesnatilimab in Healthy Chinese Adults
NCT04712006Phase 1Withdrawn
- Sponsor
- Janssen Pharmaceutical
- Start
- May 2021
- Primary completion
- Aug 2021
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label trial of NNC0142-0002 in Crohn's disease (2 arms), sponsored by Janssen Pharmaceutical. Primary endpoint: Serum Concentration of JNJ-64304500. Planned start May 2021; status: withdrawn.
02
Drugs
NNC0142-0002
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on NCT04712006.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04712006.